Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiation for Rectal Cancer
NCT00386828Phase 2Completed
- Sponsor
- BC Cancer
- Start
- Oct 2006
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in rectal cancer, sponsored by BC Cancer. Primary endpoint: Pathologic Complete Response Rate. Started Oct 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00386828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386828.